News >

Study Finds Significant Survival Disparities in HPV-related Cancer

Jason Harris
Published: Friday, Dec 08, 2017

Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities.1

“We hope that more studies in the future will focus on survival outcomes for patients with HPV-associated cancers. We also hope that the disparities described in the current article will lead to interventions aimed at improving access to cancer care irrespective of race or ethnicity,” Osazuwa-Peters et al wrote. “For a group of highly preventable cancers, the current reality exposed by Razzaghi et al is that at least one-third of all patients die within 5 years of developing an HPV-associated cancer. In some racial groups, survival is even more dismal; and all of this occurs among largely preventable cancers.”

References

  1. Razzaghi H, Saraiya M, Thompson TD, et al. Five-year relative survival for human papillomavirus-associated cancer sites [published online November 6, 2017]. Cancer. doi: 10.1002/cncr.30947.
  2. Osazuwa-Peters N, Massa ST, Simpson MC, et al. Survival of human papillomavirus-associated cancers: filling in the gaps [published online November 6, 2017]. Cancer. doi: 10.1002/cncr.30945.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x